Are Peptides Legal in Illinois? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Illinois as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Illinois attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Illinois statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Illinois has scheduled or banned on its own. The Illinois Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Illinois at a glance

State controlled-substances law: Illinois Controlled Substances Act, 720 ILCS 570; Schedule III at 720 ILCS 570/208 (codes.findlaw.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (720 ILCS 570/208(f) (Schedule III, anabolic steroids)) (codes.findlaw.com)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Department of Financial and Professional Regulation's pharmacy page posts the FDA's 16 July 2024 letter on injectable compounded semaglutide and tirzepatide: the products are not FDA approved, and the FDA received adverse-event reports tied to starting doses two to four times the approved dose and to overly fast titration. No Illinois-authored rule on salt forms or 503A copies was found (2024-07-25) (idfpr.illinois.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Illinois has no initial in-person examination requirement; telemedicine is held to the same standard of care under the Medical Practice Act (225 ILCS 60/49.5) and the Telehealth Act, and a physician or advanced practice nurse may establish the relationship and prescribe a non-controlled drug such as semaglutide by a real-time audiovisual or audio visit. Whether a questionnaire-only intake suffices is unsettled and the statute text could not be opened. (clyr.health)
State-level enforcement, 2023 to 2026: 2 actions found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Illinois, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Illinois:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Illinois. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Illinois law adds

Illinois's controlled-substances law (Illinois Controlled Substances Act, 720 ILCS 570; Schedule III at 720 ILCS 570/208) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Illinois's schedules or in a Illinois-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Section 208(f) schedules anabolic steroids and contains no reference to human growth hormone, somatropin or chorionic gonadotropin, so Illinois does not restrict HGH beyond federal law. (720 ILCS 570/208(f) (Schedule III, anabolic steroids)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

2024-07-25. The Department of Financial and Professional Regulation's pharmacy page posts the FDA's 16 July 2024 letter on injectable compounded semaglutide and tirzepatide: the products are not FDA approved, and the FDA received adverse-event reports tied to starting doses two to four times the approved dose and to overly fast titration. No Illinois-authored rule on salt forms or 503A copies was found. (idfpr.illinois.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Illinois medical board guidance specific to peptide therapy was located. A Illinois prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Illinois

Illinois' possession offence, 720 ILCS 570/402, reaches only a controlled or counterfeit substance or analog, so an individual holding an unscheduled research peptide commits no state possession offence; no general legend-drug possession crime was found, and the federal rules bind sellers. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Illinois is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Illinois has no initial in-person examination requirement; telemedicine is held to the same standard of care under the Medical Practice Act (225 ILCS 60/49.5) and the Telehealth Act, and a physician or advanced practice nurse may establish the relationship and prescribe a non-controlled drug such as semaglutide by a real-time audiovisual or audio visit. Whether a questionnaire-only intake suffices is unsettled and the statute text could not be opened. (clyr.health) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Illinois law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Illinois

2025-01-03. Attorney General Kwame Raoul's updated consumer alert says his office issued cease and desist letters to five medspas over misleading GLP-1 advertising and warns that research-only GLP-1 products should never be used by humans. (illinoisattorneygeneral.gov)
2025-02-19. Illinois co-led, with Colorado, South Carolina and Tennessee, the 38-attorney-general letter urging the FDA to act against counterfeit GLP-1s and online sellers of research-purposes-only GLP-1 active ingredients. (illinoisattorneygeneral.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The five cease and desist letters were reportedly sent to Chicago-area medspas in December 2024; the alert page itself does not date them. No medical board statement on BPC-157 or peptide clinics was found.

Frequently asked questions

Is BPC-157 legal in Illinois?

Illinois has not scheduled BPC-157, so possessing it is not a Illinois offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Illinois?

Yes. Illinois has no initial in-person examination requirement; telemedicine is held to the same standard of care under the Medical Practice Act (225 ILCS 60/49.5) and the Telehealth Act, and a physician or advanced practice nurse may establish the relationship and prescribe a non-controlled drug such as semaglutide by a real-time audiovisual or audio visit. Whether a questionnaire-only intake suffices is unsettled and the statute text could not be opened. The Illinois Board of Pharmacy position on compounded versions: The Department of Financial and Professional Regulation's pharmacy page posts the FDA's 16 July 2024 letter on injectable compounded semaglutide and tirzepatide: the products are not FDA approved, and the FDA received adverse-event reports tied to starting doses two to four times the approved dose and to overly fast titration. No Illinois-authored rule on salt forms or 503A copies was found.

Is HGH legal in Illinois?

Only with a valid prescription for an approved use. Illinois does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Illinois fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.